Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Jay R. Luly
|
| gptkbp:collaboratedWith |
gptkb:AbbVie
|
| gptkbp:focusesOn |
gptkb:COVID-19
gptkb:hepatitis_C gptkb:respiratory_syncytial_virus gptkb:hepatitis_B infectious diseases small molecule drugs |
| gptkbp:foundedYear |
1998
|
| gptkbp:headquartersLocation |
gptkb:Watertown,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Enanta Pharmaceuticals
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:notableProduct |
glecaprevir
|
| gptkbp:numberOfEmployees |
approximately 150 (as of 2023)
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
ENTA
|
| gptkbp:website |
https://www.enanta.com
|
| gptkbp:bfsParent |
gptkb:Adele_Gulfo
|
| gptkbp:bfsLayer |
6
|